These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1723118)

  • 1. Negative inotropic effects of antiarrhythmic drugs: a clinical point of view.
    Pfisterer M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S44-7. PubMed ID: 1723118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SC-36602, a new antiarrhythmic agent: comparison of its cardiovascular profile with that of other antiarrhythmic drugs.
    Frederick LG; Hatley FR; McDonald SJ; Stamm MH; Garthwaite SM
    J Cardiovasc Pharmacol; 1988 Jun; 11(6):657-66. PubMed ID: 2457760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of some antiarrhythmic drugs on systolic time intervals in normal subjects (author's transl)].
    Breithardt G; Jochum E; Kuhn H; Seipel L
    Z Kardiol; 1978 Oct; 67(10):6,0-7. PubMed ID: 366939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation.
    Di Bianco R; Gottdiener JS; Singh SN; Fletcher RD
    Angiology; 1987 Feb; 38(2 Pt 2):174-83. PubMed ID: 3103491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of negative inotropic and antiarrhythmic effects of class 1 antiarrhythmic drugs.
    Nawada T; Tanaka Y; Hirai S; Hisatome I; Hasegawa J; Kotake H; Mashiba H
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):347-55. PubMed ID: 7952796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation and heart failure: natural history and pharmacological treatment.
    Savelieva I; John Camm A
    Europace; 2004 Sep; 5 Suppl 1():S5-19. PubMed ID: 15450275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can antiarrhythmic drugs save lives in patients with congestive heart failure?
    Brendorp B; Pedersen OD; Elming H; Køber L; Torp-Pedersen C
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):191-202. PubMed ID: 15030280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotropic effects of the antiarrhythmic compound Bonnecor (AWD 19-166, GS 015).
    Nilius B; Schumann M
    Pharmazie; 1985 Dec; 40(12):854. PubMed ID: 3841601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of newer antiarrhythmic drugs in the management of patients with ventricular arrhythmias.
    Cain ME
    Angiology; 1988 Jul; 39(7 Pt 2):668-83. PubMed ID: 3044200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse cardiovascular effects of anti-arrhythmia drugs. Part II: Inotropic effects and specific pharmacokinetic properties.
    Libersa C; Caron J; Guedon-Moreau L; Adamantidis M; Nisse C
    Therapie; 1992; 47(3):199-203. PubMed ID: 1295121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacologic treatment of chronic congestive heart failure].
    Halawa B
    Przegl Lek; 1996; 53(3):119-23. PubMed ID: 8754362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
    Brown BS; Calzadilla SV; Diemer MJ; Hartman JC; Reynolds RD
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1225-34. PubMed ID: 3694532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic therapy for ventricular arrhythmias.
    Zimmermann M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S59-64. PubMed ID: 1723121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative studies on the cardiodepressant effect of disopyramide, mexiletine and propafenon].
    Angermann C; Jahrmärker H
    Z Kardiol; 1983 Nov; 72(11):665-74. PubMed ID: 6659643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk.
    Podrid PJ
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S65-73. PubMed ID: 1723122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF; Morganroth J
    Compr Ther; 1987 Apr; 13(4):26-35. PubMed ID: 3105950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
    Uchida Y; Kawada M; Sawanobori K; Sonoki H; Inoue K; Mizuno K; Itou T; Tabunoki Y; Tsukamoto M; Ohashi Y; Kyotani Y; Shimizu N; Fujii M; Nakamura M
    Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiarrhythmic drugs in atrial fibrillation].
    Brembilla-Perrot B
    Rev Prat; 2002 Jun; 52(12):1317-23. PubMed ID: 12187895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible involvement of sodium channel blockade of class-I-type antiarrhythmic agents in postischemic contractile recovery of isolated, perfused hearts.
    Takeo S; Tanonaka K; Hayashi M; Yamamoto K; Liu JX; Kamiyama T; Yamaguchi N; Miura A; Natsukawa T
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1403-9. PubMed ID: 7791114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.